Watson in talks to acquire Actavis
The US generic drugmaker is in talks to acquire its Swiss rival in a deal that could value Actavis at around €4.5bn, according to people familiar with the matter
FT.com – European companies
The US generic drugmaker is in talks to acquire its Swiss rival in a deal that could value Actavis at around €4.5bn, according to people familiar with the matter
FT.com – European companies